Heart failure (HF) is driven by the interplay between regulatory transcription factors and dynamic alterations in chromatin structure. Pathologic gene transactivation in HF is associated with recruitment of histone acetyl-transferases and local chromatin hyperacetylation. We therefore assessed the role of acetyl-lysine reader proteins, or bromodomains, in HF. Using a chemical genetic approach, we establish a central role for BET family bromodomain proteins in gene control during HF pathogenesis. BET inhibition potently suppresses cardiomyocyte hypertrophy in vitro and pathologic cardiac remodeling in vivo. Integrative transcriptional and epigenomic analyses reveal that BET proteins function mechanistically as pause-release factors critical to expression of genes that are central to HF pathogenesis and relevant to the pathobiology of failing human hearts. This study implicates epigenetic readers as essential effectors of transcriptional pause release during HF pathogenesis and identifies BET coactivator proteins as therapeutic targets in the heart.
INTRODUCTION
Heart failure (HF) is a leading cause of healthcare expenditures, hospitalization, and mortality in modern society (Hill and Olson, 2008; Roger et al., 2012) . HF occurs when the heart is unable to maintain organ perfusion at a level sufficient to meet tissue demand and results in fatigue, breathlessness, multiorgan dysfunction, and early death. Existing pharmacotherapies for individuals afflicted with HF, such as b adrenergic receptor antagonists and inhibitors of the renin-angiotensin system, generally target neurohormonal signaling pathways. While such therapies have improved survival in HF patients, residual morbidity and mortality remain unacceptably high (Roger et al., 2012) . In light of this unmet clinical need, the elucidation of novel mechanisms involved in HF pathogenesis holds the promise of identifying new therapies for this prevalent and deadly disease.
In response to diverse hemodynamic and neurohormonal insults, the heart undergoes pathologic remodeling, a process characterized by increased cardiomyocyte (CM) volume (hypertrophy), interstitial fibrosis, inflammatory pathway activation, and cellular dysfunction culminating in contractile failure (Hill and Olson, 2008; Sano et al., 2002; van Berlo et al., 2013) . The pathologic nature of this process has been validated in large epidemiologic studies, which demonstrate that the presence of chronic cardiac hypertrophy is a robust predictor of subsequent HF and death (Hill and Olson, 2008; Levy et al., 1990) . Although hypertrophic remodeling may provide short-term adaptation to pathologic stress, sustained activation of this process is maladaptive and drives disease progression (Hill and Olson, 2008) . Studies over the past decade have clearly demonstrated that inhibition of specific prohypertrophic signaling effectors exerts cardioprotective effects even in the face of persistent stress. Together, these data provide a cogent rationale that targeting the hypertrophic process itself can be beneficial without compromising contractile performance (Hill and Olson, 2008; van Berlo et al., 2013) .
Hemodynamic and neurohormonal stressors activate a network of cardiac signal transduction cascades that ultimately converge on a defined set of transcription factors (TFs), which control the cellular state of the CM (Hill and Olson, 2008; Lee and Young, 2013; van Berlo et al., 2013) . Studies in animal models have implicated several master TFs that drive HF progression (e.g., NFAT, GATA4, NFkB, MEF2, c-Myc) via induction of pathologic gene expression programs that weaken cardiac performance (Hill and Olson, 2008; Maier et al., 2012; van Berlo et al., 2011; Zhong et al., 2006) . In addition to stimulus-coupled activation of DNA-binding proteins, changes in cell state occur through an interplay between these master regulatory TFs and changes in chromatin structure . Notably, stress pathways activated in HF are associated with dynamic remodeling of chromatin (McKinsey and Olson, 2005; Sayed et al., 2013) , including global changes in histone acetylation and DNA methylation. As alterations in higher-order chromatin structure modulate the net output of multiple, simultaneously activated transcriptional networks Schreiber and Bernstein, 2002) , manipulation of cardiac gene control via targeting of chromatin-dependent signal transduction represents a potentially powerful therapeutic approach to abrogate pathologic gene expression and HF progression.
Transcriptional activation is associated with local N-ε-acetylation of lysine sidechains on the unstructured amino-terminal tail of histone proteins (Schreiber and Bernstein, 2002) . Dynamic positioning of acetyl-lysine (Kac) arises from the interplay of so-called epigenetic ''writers'' (histone acetyltransferases or HATs) and epigenetic ''erasers'' (histone deacetylases or HDACs). Context-specific recognition of Kac at regions of actively transcribed euchromatin is mediated by epigenetic ''reader'' proteins possessing a Kac-recognition module or bromodomain . Molecular recognition of Kac by bromodomain-containing proteins serves to increase the effective molarity of transcriptional complexes promoting chromatin remodeling, transcriptional initiation, and elongation (Dawson et al., 2012) . Elegant studies over the past decade have implicated both epigenetic writers (e.g., EP300) (Wei et al., 2008) and erasers (e.g., HDACs) (Montgomery et al., 2007; Trivedi et al., 2007; Zhang et al., 2002) in cardiac development and disease. In contrast, little is known about epigenetic readers in cardiac biology.
Members of the bromodomain and extraterminal (BET) family of bromodomain-containing reader proteins (BRD2, BRD3, BRD4, and testis-specific BRDT) associate with acetylated chromatin and facilitate transcriptional activation by recruitment of coregulatory complexes such as mediator (Jiang et al., 1998) and the positive transcription elongation factor b (P-TEFb) (Hargreaves et al., 2009; Jang et al., 2005; Yang et al., 2005) . Recently, we developed a first-in-class potent, selective bromodomain inhibitor, JQ1, which displaces BET bromodomains from chromatin resulting in suppression of downstream signaling events to RNA polymerase II (Pol II) (Delmore et al., 2011; Filippakopoulos et al., 2010) . We and others have utilized this chemical genetic tool to probe BET function in a number of developmental and disease contexts, such as cancer (Delmore et al., 2011; Filippakopoulos et al., 2010) , HIV infection (Banerjee et al., 2012) , and spermatogenesis (Matzuk et al., 2012) . The role of BET bromodomain proteins in the heart remains unknown.
In this study, we report that BETs are critical effectors of pathologic cardiac remodeling via their ability to coactivate defined stress-induced transcriptional programs in the heart. An important mechanism by which BETs drive pathologic gene induction is via their ability to promote transcriptional pause release and elongation, thereby coactivating multiple master TFs known to initiate and promote HF. The elucidation of BET function in the heart implicates epigenetic reader proteins in cardiac biology and HF pathogenesis. Moreover, use of chemical biology to specifically probe the role of BET bromodomain-containing proteins in the myocardium suggests that targeted manipulation of chromatin-based signal transduction might be harnessed for therapeutic gain in heart disease.
RESULTS

BET Bromodomains Are Cell-Autonomous Regulators of Pathologic Cardiomyocyte Hypertrophy In Vitro
Because pathologic cardiac hypertrophy features coordinate transcriptional activation of numerous master regulatory TFs, we hypothesized that BET bromodomains would function as coactivator proteins in this disease process. We first assessed the expression patterns of BETs in the heart. Analysis of neonatal rat ventricular cardiomyocytes (NRVM) and adult mouse ventricular tissue revealed that Brd2, Brd3, and Brd4 are transcribed, with Brd4 emerging as most highly expressed (Figures S1A and S1B available online). Western blots in NRVM, mouse heart tissue, and human heart tissue confirmed abundant BRD4 expression ( Figure S1C ) and immunofluorescence staining of NRVM demonstrated BRD4 to be nuclear localized ( Figure S1D ). First, using a chemical biology approach, we leveraged the validated small-molecule probe of BET bromodomain function, JQ1 ( Figure 1A ), in the established NRVM model in vitro (Simpson et al., 1982) . Nanomolar doses of JQ1 significantly blocked phenylephrine (PE)-mediated cellular hypertrophy ( Figure 1B ) and pathologic gene induction ( Figure 1C ). In a similar manner, knockdown of Brd4 in NRVM ( Figure S1E ) also attenuated PEmediated hypertrophic growth ( Figure 1D ) and pathologic gene induction ( Figure 1E ). We next assessed a number of structurally dissimilar BET inhibitors (I-BET, I-BET-151, RVX-208, and PFI-1; chemical structures shown in Figure S1F ) for their ability to inhibit CM hypertrophy. At equimolar doses, we found that inhibition of agonist-induced CM hypertrophy was indeed a class effect of BET inhibitors, with the relative potency of these compounds correlating with their known IC 50 against BRD4 (Filippakopoulos et al., 2010) . Together, these data implicate BET bromodomain proteins as putative cell-autonomous regulators of pathologic CM hypertrophy and identify potent antihypertrophic effects of the small-molecule BET inhibitor JQ1 in vitro.
BETs Are Required for Induction of a Pathologic Gene Expression Program in Cardiomyocytes
To determine the transcriptional effects of BET bromodomain inhibition during CM hypertrophy, we performed gene expression profiling (GEP) studies in cultured NRVM at baseline and after PE stimulation (1.5, 6, and 48 hr) in the presence or absence of JQ1. These three time points capture induction of early response genes such as c-Myc (Zhong et al., 2006) , as well as the late hypertrophic expression program. Assessment of differentially expressed transcripts revealed three major clusters: genes that were PE inducible and suppressed by JQ1, genes that were PE inducible and unaffected by JQ1, and genes that were PE suppressed and unaffected by JQ1. A heatmap of genes selected based on the highest magnitude of PE-mediated change illustrates each of these clusters (Figure 2A ; full list of Table S1 ). Global analysis of GEPs revealed that PE stimulation resulted in the cumulative induction of over 450 genes and that JQ1 abrogated induction of a substantial subset of PE-inducible genes. Statistically significant transcriptional effects were evident as early as 1.5 hr and increased over time (Figures 2B and 2C) , consistent with the emerging role of BETs as coactivators of inducible gene expression programs (Nicodeme et al., 2010) . Functional pathway analysis of PE-inducible transcripts that were suppressed by JQ1 revealed that BETs facilitate expression of a host of biological processes known to be involved in pathologic CM activation, including cytoskeletal reorganization, extracellular matrix production, cell-cycle reentry, paracrine/autocrine stimulation of cellular growth, and proinflammatory signaling ( Figure 2D ) (Song et al., 2012) . Using the prohypertrophic cytokine Il6 as a representative target ( Figure 2C ), we confirmed by qRT-PCR that JQ1 significantly attenuated PE-mediated induction (Figure 2E) . Activity of BETs during pathologic stress was not due to PE-mediated increases in BET expression ( Figure S2 ). Chromatin immunoprecipitation (ChIP) studies demonstrated BRD4 occupancy at the Il6 locus and an increase in BRD4 enrichment after 90 min of PE stimulation that was blocked by BET inhibition ( Figure 2F ). Interestingly, BET bromodomain inhibition did not affect PE-mediated induction of Myc ( Figure 2G ), an established transcriptional driver of pathologic cardiac hypertrophy (Zhong et al., 2006) . Prior studies from our laboratory and others have implicated BET bromodomains in neoplastic MYC transcription in hematopoietic tumors (Delmore et al., 2011; Zuber et al., 2011) . Collectively, these in vitro data (Figures 1 and 2 ) demonstrate that BET bromodomain-containing proteins regulate CM hypertrophy in a cell-autonomous manner via coactivation of a broad but specific transcriptional program.
BET Bromodomain Inhibition Arrests Pathologic
Hypertrophy and Heart Failure In Vivo Given these observations in cultured CMs, we hypothesized that BETs might regulate pathologic cardiac remodeling in the intact organism. We leveraged the favorable therapeutic index of JQ1, which has previously been shown to potently inhibit BET bromodomain function in adult mice without significant toxicity when administered chronically at 50 mg/kg/day (Filippakopoulos et al., 2010) . Independently, we confirmed the lack of overt toxicity by treating mice with JQ1 for 2-3 weeks, observing no effect on endurance exercise capacity ( Figure S3A ), a metric of global cardiometabolic health. For in vivo studies, we first used transverse aortic constriction (TAC), a thoroughly characterized model of cardiac pressure overload, which provides focal hemodynamic stress to the heart and recapitulates several cardinal aspects of pathologic hypertrophy and HF in humans (Rockman et al., 1991) . In our hands, adult mice subject to TAC develop concentric left ventricular hypertrophy (LVH) by 7-10 days and progress to advanced HF after 3-4 weeks.
We performed TAC or sham surgery, followed by administration of JQ1 (50 mg/kg/day versus vehicle control) beginning 1.5 days after initiation of TAC ( Figure 3A ). Serial echocardiography showed that JQ1 protected against TAC-mediated LV systolic dysfunction, cavity dilation, and wall thickening, with effects that were sustained out to 4 weeks (Figures 3B-3D and S3B; Movies S1 and S2). JQ1 treatment also inhibited pathologic cardiomegaly ( Figure 3E ; representative photos in Figure 3F ), pulmonary congestion ( Figure 3G ), and myocardial expression of canonical hypertrophic marker genes ( Figure 3H ) after TAC. JQ1 was well tolerated, as evidenced by normal activity (Movies S3 and S4) and the lack of significant mortality or weight loss compared to vehicle-treated mice (data not shown). In addition, JQ1 had no adverse effect on LV structure or function in shamtreated mice ( Figures 3E, 3F , and S3B). Importantly, JQ1 does not affect systemic blood pressure ( Figure S3C ). Furthermore, the protective effects of JQ1 in the TAC model were not associated with differences in the pressure gradient across the aortic constriction ( Figure S3D ).
In addition to hemodynamic stress, excessive neurohormonal activation is also a central driver of pathologic cardiac hypertrophy (Hill and Olson, 2008; van Berlo et al., 2013) . Therefore, we next assessed whether JQ1 could ameliorate pathology in a second mouse model of neurohormonally mediated cardiac hypertrophy. Mice were implanted with osmotic minipumps delivering phenylephrine (PE, 75 mg/kg/day versus saline) followed by JQ1 or vehicle administration beginning 1.5 days after minipump installation. This infusion protocol produces robust concentric LVH in 2-3 weeks but does not cause significant LV cavity dilation or depression of LV systolic function in wild-type mice. Concordant with our TAC results above, JQ1 potently suppressed the development of pathologic cardiac hypertrophy during chronic PE infusion, without any compromise in LV systolic function ( Figure 3I ).
In addition to favorable effects on cardiac function, we assessed whether JQ1 also ameliorated cardinal histopathologic features of HF in vivo. Analysis of mouse heart tissue demonstrated that JQ1 significantly attenuated the development of CM hypertrophy ( Figure 4A ), myocardial fibrosis ( Figure 4B ), apoptotic cell death ( Figure 4C ), and capillary rarefaction (F) BRD4 ChIP-qPCR in NRVM treated with JQ1 (500 nM) and PE (100 mM) for 90 min. Target and nontarget (À4 kb region) primers depicted. n = 3, *p < 0.05 versus veh, # p < 0.05 versus PE.
(G) Myc qRT-PCR in NRVM treated with JQ1 (500 nM) and PE (100 mM, n = 4). *p < 0.05 versus veh, # p < 0.05 versus PE. Data shown as mean ± SEM.
See also Figure S2 and Table S1 . (I) PE infusion (75 mg/kg/day) and JQ1 administration (n = 7 PE, n = 5 normal saline). *p < 0.05 versus NS veh. **p < 0.05 versus PE veh. Data shown as mean ± SEM. See also Figure S3 and Movies S1, S2, S3, and S4.
( Figure 4D ) typically seen after 4 weeks of TAC (Sano et al., 2007; Song et al., 2010) .
BET Inhibition Suppresses a Pathologic Cardiac Gene Expression Program In Vivo
Using the TAC model, we performed detailed transcriptional analysis in three groups (sham vehicle, TAC vehicle, and TAC-JQ1) at three time points ( Figure 5A ): 3 days (to reflect early events that occur prior to the onset of hypertrophy), 11 days (established hypertrophy), and 28 days (advanced pathologic remodeling with signs of HF). Unsupervised hierarchical clustering revealed that the TAC-veh group had a distinct GEP signature that evolved with time when compared to the sham-veh group ( Figure 5B ). In contrast, TAC-JQ1 clustered with the sham group and displayed no significant temporal change despite continuous exposure to TAC ( Figure 5B ). Hence, JQ1 treatment suppressed the evolution of a broad pathologic gene expression program in the heart, with effects evident as early as 3 days post-TAC. Similar to our studies in isolated CMs (Figure 2 ), global GEP analysis revealed three major clusters: genes that were TAC inducible and suppressed by JQ1, those that were TAC inducible and unaffected by JQ1, and those that were TAC suppressed and unaffected by JQ1. A representative heatmap of genes (selected for the highest magnitude of TAC-mediated change) highlights each of these three clusters ( Figure 5C ; full list of differential transcripts provided in Table S2 ). TAC did not significantly alter myocardial expression of Brd2, Brd3, or Brd4 ( Figure S4A ). To visualize the global transcriptional effects of TAC and BET bromodomain inhibition in the model over time, we performed gene expression dynamics inspector (GEDI) analysis (Eichler et al., 2003) . Although the sham mosaic remained temporally invariant, TAC resulted in progressive induction of gene clusters over time, indicated by increased signal in numerous tiles within the mosaic ( Figure 5D ). BET bromodomain inhibition disrupted the temporal evolution of this TAC-induced, pathologic transcriptional program with a mosaic signature that more closely resembled the sham group ( Figure 5D ). A volcano plot showing fold change effect of TAC-JQ1 versus TAC vehicle (shades of blue) on the set of all genes upregulated at any time point by TAC (shades of red) is shown in Figure 5E . These data illustrate the potent and statistically significant effects of JQ1 in suppressing TAC-mediated gene induction. Additionally, comparison of fold change effect of TAC-JQ1 versus sham vehicle (shades of blue) on the set of all genes upregulated at any time point by TAC (shades of red) shows that JQ1 administration reversed TAC-mediated gene induction to levels similar to those in the sham-treated hearts ( Figure S4B ). Functional pathway analysis of TAC-inducible transcripts that were suppressed by JQ1 showed enrichment for key biological processes involved in pathologic myocardial remodeling and HF progression in vivo ( Figure 5F ) (Song et al., 2012; Zhao et al., 2004) . Importantly, these functional terms aligned with the data from isolated NRVM ( Figure 2D ) and represent pathologic processes universally observed in advanced human HF (Hannenhalli et al., 2006) .
Given the broad effects on myocardial gene expression seen with JQ1, we hypothesized that BETs enable pathologic gene induction via their ability to coordinately coactivate multiple TF pathways in vivo. Using gene set enrichment analysis (GSEA) (Subramanian et al., 2005) , we compared our set of TAC-inducible genes that were suppressed by BET inhibition, against compendia of TF signatures. Specifically, we studied the Broad Institute Molecular Signatures Database C3 motif gene sets (Xie et al., 2005) , as well as three functional, in vivo signatures of CMspecific transcriptional effectors: Calcineurin-NFAT (Bousette et al., 2010) , NFkB (Maier et al., 2012) , and GATA4 (Heineke et al., 2007) . These analyses revealed that the TAC-induced gene expression profile was positively enriched for IRF and ETS consensus binding motifs (family-wise error rate [FWER] p < 0.0001), as well as for myocardial signatures that result from Calcineurin-A, NFkB, and GATA4 activation ( Figure 5G) . Conversely, the effect of JQ1 demonstrated strong negative enrichment for these same TF signatures ( Figure 5G ; FWER p < 0.0001 for IRF and ETS motifs). In contrast, although TAC was strongly correlated with both c-Myc and E2F signatures, there was no significant correlation between c-Myc/E2F and JQ1 effect at any time point ( Figure S4C ). Consistent with our NRVM studies, we also found that JQ1 had no effect on TACmediated induction of Myc expression in vivo ( Figure S4D) . Hence, the GSEA data support a model in which BET bromodomains facilitate gene induction via coactivation of specific myocardial TF networks.
We next compared the set of TAC-inducible genes that were suppressed by JQ1 against validated gene expression profiles of advanced nonischemic and ischemic HF in humans (Hannenhalli et al., 2006) . This analysis demonstrated that targets of BETs in the mouse TAC model overlapped in a statistically significant manner with the set of genes induced in human HF ( Figure S4E ; c 2 < 5 3 10 À14 ). Interestingly, the vast majority (89%) of these targets were common to both ischemic and nonischemic human HF ( Figure S4F ). Thus, inasmuch as the gene expression profiles of mice subjected to TAC overlap with that of advanced HF in a human cohort, we found the principal transcriptional targets of BET bromodomains in mice were also relevant in human disease.
BET Bromodomain Inhibition Abrogates Transcriptional Pause Release Genome wide during Pathologic Hypertrophy In Vivo
To establish the mechanism by which BET bromodomain inhibition impairs global transactivation of pathologic transcriptional programs concomitantly activated during pressure overload, we performed ChIP coupled with high-throughput genome sequencing (ChIP-seq) on heart tissue from mice subjected to sham versus TAC surgery, with and without JQ1 treatment. For (F) DAVID analysis of genes that were TAC-induced and JQ1-reversed. FDR < 5% considered statistically significant. (G) GSEA for TAC veh and TAC-JQ1 against three independent GEPs derived from CM-specific activation of canonical prohypertrophic transcriptional effectors in vivo: Calcineurin-NFAT (driven by a constitutively active Calcineurin-A (CnA) transgene [Bousette et al., 2010] , NFkB driven by an IKK2 transgene [Maier et al., 2012] and transgenic GATA4 overexpression [Heineke et al., 2007] ). FWER p < 0.250 represents statistically significant enrichment. Data representative for all three time points. Plots shown for 28 day time point. Data shown as mean ± SEM. See also Figure S4 and Table S2 .
heart tissue ChIP-seq, a 4 day time point was chosen to capture changes in chromatin state that occur during the initial phase of hypertrophic growth in the TAC model ($3-7 days). Experimental data obtained for BRD4 and Pol II were integrated with publicly available data from Bing Ren and colleagues, which provided epigenomic landscapes for murine cardiac euchromatin (Shen et al., 2012) . Genome-wide data for Pol II enrichment in our sham operated mice demonstrated excellent statistical agreement with Pol II enrichment curated from the literature (R 2 = 0.65; Figures S5A and S5B ).
First, we determined the sites of genome-wide localization of BRD4 in the murine heart. Strong enrichment was observed at promoter regions of actively transcribed genes, as identified by enrichment for histone 3 lysine 4 trimethylation (H3K4me3) and Pol II ( Figure 6A ). Rank ordering of all transcriptionally active promoters by Pol II occupancy identified global binding of BRD4 at sites of transcriptional initiation. Recently, BET bromodomains have also been shown to bind to enhancer elements in the eukaryotic genome (Lové n et al., 2013; Zhang et al., 2012) . Binding of BRD4 to enhancer elements was assessed by rankordering regions of enrichment for histone 3 lysine 27 acetylation (H3K27ac) and comparing BRD4 enrichment to that of P300, a known enhancer factor of functional significance in cardiac hypertrophy (Wei et al., 2008) . Importantly, BRD4 binds to the vast majority of active enhancers in the murine cardiac genome ( Figure 6B ).
BRD4, through its C-terminal domain (CTD), physically associates with and activates CDK9 (Bisgrove et al., 2007; Jang et al., 2005; Yang et al., 2005) , a core component of the P-TEFb complex, which functions as an elongation-promoting Pol II CTD kinase (Peterlin and Price, 2006) . Hyperactivation of P-TEFb and consequent increases in global transcription are considered a hallmark of pathologic cardiac hypertrophy in multiple systems (Espinoza-Derout et al., 2009; Sano et al., 2002; Yoshikawa et al., 2012) . Inhibition of CDK9 function in NRVM has been shown to attenuate endothelin-1-mediated hypertrophy in vitro (Sano et al., 2002) . These observations provided us with a rationale to explore the effect of BET bromodomain inhibition on transcriptional elongation in the TAC model in vivo.
BET bromodomain inhibition by JQ1 has been shown to displace BRD4 and P-TEFb from chromatin leading to a decrease in Pol II elongation at active genes (Lové n et al., 2013). Gene-specific effects on Pol II occupancy were explored at canonical mediators and effectors of pathologic cardiac remodeling. As shown for representative genes in Figures 6C  and 6D , sham-treated hearts feature a pronounced Pol II enrichment peak at the TSS of Ctgf and Serpine1 (SerpinE1/PAI-1), with only modest evidence of downstream elongation (gray wiggle plots). Following TAC, transcriptional activation (as shown in Figure 5C and Table S2 ) was accompanied by a shift in the distribution of gene bound Pol II toward a higher relative occupancy in the elongating gene body region (black wiggle plots; Figures 6C and 6D) . BET bromodomain inhibition markedly attenuated Pol II occupancy in the elongating region, leading to higher relative Pol II occupancy at the TSS initiation site (red wiggle plots), consistent with its ability to attenuate transcription elongation. Additional representative Pol II enrichment plots for the Ace, Bgn, Thbs1, and Xirp2 loci are shown in Figure S5C .
Global effects of BET bromodomain inhibition on initiation and elongation were further examined by calculating the Pol II traveling ratio at all actively transcribed genes and on the subset of genes induced by TAC. Traveling ratio is a validated measure of transcriptional pause release that compares promoter and elongating gene body occupancy levels of Pol II to quantify the ratio of paused to elongating Pol II (Lin et al., 2012; Wade and Struhl, 2008) . BET bromodomain inhibition of TAC-treated hearts led to a higher ratio of promoter to elongating gene body Pol II compared to TAC at all active genes ( Figure 6E ) and at TACinduced genes that were reversed by JQ1 ( Figure 6F) . A metagene analysis of Pol II enrichment among actively transcribed genes verified the change in the ratio of promoter to elongating gene body Pol II by JQ1 ( Figure S5D ). The effects of JQ1 on transcriptional elongation in the TAC model were reproduced in an independent in vivo biological replicate, as shown in Figure S5E .
Given the high variability in dynamic range between heart tissue samples ChIP-seq ( Figure S5F ) and the relative nature of metrics such as the traveling ratio, we examined global levels of initiating and elongating Pol II to further quantify the effects of BET bromodomain inhibition. We observed a specific decrease in the elongation-specific serine 2 Pol II phosphoform (Ser2P) upon JQ1 treatment ( Figure 6G ) with little change to the initiation-specific serine 5 Pol II phosphoform (Ser5P) ( Figure 6H ). JQ1-mediated suppression of Pol II Ser2P abundance was recapitulated in the in vitro NRVM model ( Figure S5G ). Interestingly, we also observed significant upregulation of the P-TEFb inhibitory protein HEXIM1 (Espinoza-Derout et al., 2009; Peterlin and Price, 2006; Yoshikawa et al., 2012) during JQ1 treatment, suggesting an additional mechanism by which BET bromodomain inhibition may inhibit transcriptional elongation ( Figures S5H-S5K ). We conclude that transcriptional elongation is an important mechanism by which BET bromodomain inhibition attenuates gene expression programs activated during pathologic cardiac hypertrophy.
DISCUSSION
Our current work implicates BET bromodomain reader proteins as essential transcriptional coactivators of a pathologic gene expression program that drives CM hypertrophy and HF progression. Gene-expression profiling and ChIP-seq studies reveal that BET proteins function, in part, by promoting transcriptional pause release during pathologic stress. In broadest terms, the data presented here directly implicate epigenetic readers in cardiac biology and identify BET bromodomain proteins as potential therapeutic targets in heart disease.
Pathologic cardiac hypertrophy ensues by a collaborative interplay between master regulatory TFs and dynamic changes in chromatin structure . TFs including NFAT, GATA4, and NFkB (Hill and Olson, 2008; Maier et al., 2012; van Berlo et al., 2011) , as well as histone modifying enzymes such as EP300 and HDAC2 (Trivedi et al., 2007; Wei et al., 2008; Zhang et al., 2002) activate a CM gene expression program that results in cellular dysfunction. Dynamic and global changes in histone 3 lysine 9 acetylation, a chromatin mark for gene promoters and enhancers, have been observed genomewide in the adult mouse heart after pressure overload (Sayed et al., 2013) . Despite these fundamental observations, the mediators in the heart that link the activity of master regulatory TFs and histone acetylation to Pol II dynamics and global transcriptional anabolism are poorly understood.
Here, we establish that BET bromodomain reader proteins function critically in chromatin-mediated signal transduction to Pol II, coactivating pathologic gene expression in the heart. GSEA reveals that BET inhibition antagonizes multiple TF outputs known to be causal in HF pathogenesis including NFAT, NFkB, and GATA4, suggesting that BET bromodomain proteins coactivate a broad transcriptional network involving multiple TFs. Importantly, we find that BET bromodomain proteins do not directly affect Myc mRNA levels or function in the heart-a striking contrast to observations in hematopoietic tumors, where BETs are required for c-Myc expression and activity (Delmore et al., 2011; Zuber et al., 2011) . ChIP-seq analysis reveals that BRD4 co-occupies active promoters with Pol II (as defined by H3K4me3) and active gene enhancers (as defined by H3K27ac) in the adult mouse heart and that cardiac pressure overload induces Pol II pause release and transcriptional elongation within 4 days. BET bromodomain inhibition suppresses transcriptional pause release during pressure overload in vivo and attenuates expression of the pathologic HF gene program. Together, these data demonstrate that BET bromodomain reader proteins are indispensable coactivators in pathologic gene expression in the heart that function, in part, through their ability to promote Pol II pause release and transcriptional elongation.
Activation of the P-TEFb complex, a central effector of pause release and transcriptional elongation , has been observed in pathologic cardiac hypertrophy (Sano et al., 2002) . Previous studies in NIH 3T3 cells and macrophages have demonstrated that BRD4 interacts with P-TEFb and facilitates stimulus-coupled recruitment of P-TEFb to target promoters (Hargreaves et al., 2009; Patel et al., 2013) . Activity of CDK9, a core constituent of the P-TEFb complex, is also increased during hypertrophic stress and is required for agonist-induced hypertrophy in NRVM (Sano et al., 2002) . CMspecific overexpression of the CDK9-activating protein CyclinT1 results in cardiac hypertrophy in vivo (Sano et al., 2007) . In addition, deficiency of HEXIM-1, a nuclear protein that sequesters the P-TEFb in an inactive complex, has been shown to potentiate pathologic hypertrophy in vivo (Espinoza-Derout et al., 2009 ). In our studies, localization of BRD4 with promoter-enhancer (C and D) Gene tracks at (C) Ctgf and (D) Serpine1 gene in heart. BRD4 (red) is from sham-treated hearts. H3K27ac (green) and H3K4me3 (orange) derived from published landscapes of wild-type mouse hearts (Shen et al., 2012) that are age/sex/strain-matched to our sham-treated hearts. Pol II are from either sham (gray), TAC (black), or TAC+JQ1-treated (red) heart. x axis shows genomic position. y axis shows ChIP-seq occupancy (rpm/bp). (E and F) Empirical cumulative distribution plots of Pol II traveling ratios (TR) (Rahl et al., 2010) for genes that are transcriptionally active in either sham or TAC-treated hearts (E) and genes that are TAC induced and reversed by JQ1 (F). Differences in TR distribution between TAC and TAC+JQ1-treated hearts are statistically significant (*** Welch's two-tailed t test, p < 2 3 10 À16 ).
(G and H) Western blots with densitometry of heart tissue nuclear extracts from sham, TAC, and TAC+JQ1-treated hearts for total Pol II or indicated phosphoforms (n = 3; # p < 0.05 versus TAC veh). Data shown as mean ± SEM. See also Figure S5 and Table S3 .
elements and the suppression of pause release with BET bromodomain inhibition in the TAC model ( Figure 6 ) suggest BETs facilitate pause release at these gene loci. The robust induction of HEXIM1 expression we observed following BET bromodomain inhibition ( Figures S5H-S5K ) may also serve to suppress P-TEFb activity and reduce Pol II pause release. Concordant reductions in Ser2 phosphorylation of the Pol II CTD ( Figure 6G and S5G), a specific target of the P-TEFb complex, both in vitro and in vivo, support these mechanisms of action. Defining the extent to which BETs alter transcriptional elongation through direct interactions with components of the P-TEFb complex (Bisgrove et al., 2007) or regulation of HEXIM-1 expression represent important avenues of future investigation. Although evidence presented here does implicate BETs in the regulation of P-TEFb function and Pol II pause release during TAC, we cannot exclude additional effects of BET bromodomains on Pol II initiation at specific gene promoters. Consistent with our findings, other work has previously identified that Pol II pause release is a dominant mechanism for gene induction in both the developing heart and in the adult mouse heart during pressure overload, with de novo Pol II recruitment occurring at only 5% of induced genes in the TAC model (Sayed et al., 2013) . Potential roles for BET bromodomain proteins in locusspecific Pol II initiation in the heart, or in other aspects of mRNA processing, are the subject of ongoing research by our group. Furthermore, the very recent discovery of asymmetrically loaded BRD4 on a critical subset of state-specific enhancers termed superenhancers (Lové n et al., 2013) raises the possibility that such superenhancers might also be active in the stressed myocardium and contribute to BET target specificity.
HF is known to progress via pathologic crosstalk between CMs and cardiac fibroblasts (van Berlo et al., 2013) . Although the TAC model of HF provides a relatively focal stress to the heart, and JQ1 attenuates pathologic remodeling without effects on blood pressure or hemodynamic load ( Figures S3C and S3D) , we recognize that BET bromodomain inhibition in vivo may act on cardiac fibroblasts and other cell types that populate the stressed myocardium, in addition to the observed effects on CMs. We show here that BET bromodomain inhibition or Brd4 knockdown in isolated NRVM both attenuate pathologic CM hypertrophy in vitro (Figure 1 ). In addition, we find that Brd4 is the highest expressed BET gene in isolated CMs and in adult heart tissue. These data identify a cell-autonomous role for BRD4 in CMs in vitro and suggest that this protein might be an important target of BET bromodomain inhibitors in the heart in vivo. Future studies using cell type and temporally restricted gene deletion of Brd4 and other BET family members in adult mice will help annotate their gene-and tissue-specific functions in experimental models of HF.
In conclusion, this study implicates a family of conserved epigenetic reader proteins as essential components of the transcriptional machinery that drives pathologic cardiac remodeling and HF. BET bromodomain proteins function as master regulatory TF coactivators that regulate pathologic pause release in the failing heart. The chemical biological approach leveraged here in rodent models of pathologic hypertrophy and HF provides a rationale for developing drug-like BET bromodomain inhibitors as investigational therapeutic agents in heart disease.
EXPERIMENTAL PROCEDURES Animal Models
All protocols concerning animal use were approved by the Institutional Animal Care and Use Committee at Case Western Reserve University and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All models were conducted in C57Bl/6J mice (Jackson Laboratories), which were maintained in a pathogen-free facility with standard light/dark cycling and access to food and water ad libitum.
Human Samples LV samples from healthy human hearts were obtained as described (Hannenhalli et al., 2006; Margulies et al., 2005) in accordance with the Investigation Review Committee at the Hospital of the University of Pennsylvania, Philadelphia, PA. Nuclear protein was extracted using the NE-Per kit (Thermo Scientific, 78833) according to manufacturer's instructions. Gene expression profiles from left ventricles obtained from nonfailing versus failing human hearts were curated from a published data set (Hannenhalli et al., 2006) .
Statistical Analysis
Data are reported as mean ± standard error. The statistical methods used in analysis of microarray and ChIP-seq data are detailed separately. Comparison of means between two groups was analyzed using a two-tailed Student's t test with Bonferroni correction for multiple comparisons. For all analyses, p values < 0.05 were considered significant.
ACCESSION NUMBERS
The GEO accession number for the ChIP-seq, mouse microarray, and rat microarray data is GSE48112. The GEO accession numbers for the individual GEO series corresponding to the ChIP-seq, mouse microarray, and rat microarray are GSE46668 (ChIP-seq), GSE48110 (mouse heart), and GSE48111 (NRVM).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five figures, three tables, and four movies and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2013.07.013.
